Case Report of Acute Aortic Dissection during Treatment with Capecitabine for a Late Recurrence of Breast Cancer

Sclafani, Francesco; Carnaghi, Carlo; Colombo, Piergiuseppe; Bozzarelli, Silvia; Vincenzo, Fabio De; Rimassa, Lorenza; Giorgetti, P. L.; Santoro, Armando

doi:10.1159/000316331

Cited by 7 publications

(3 citation statements)

References 15 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Cardiotoxicity due to 5-FU is the second most frequent cause of chemotherapeutic-related cardiac toxicity after anthracyclines [9]. Cardiac side effects of capecitabine vary from angina to myocardial infarction [10,11]. The incidence of 5-FU-induced cardiac toxicity is about 1.2–7.6%, and the incidence of life-threatening toxicity is <1% [12].…”

Section: Discussionmentioning

confidence: 99%

Clinical and Electrocardiography Changes in Patients Treated with Capecitabine

Koca

Salman²,

Ünek³

et al. 2011

Chemotherapy

View full text Add to dashboard Cite

Background: We aimed to identify the incidence of cardiac events with capecitabine treatment. Methods: The study included 52 patients (median age 59 years) with cancer treated at our Medical Oncology Clinic between 2009 and 2010. Cardiac events from capecitabine treatment were classified into 4 groups: cardiac symptoms, physical signs, electrocardiography (ECG) findings, and severe adverse cardiac effects. Results: The patients received either single-agent capecitabine or a combination chemotherapy including capecitabine. After initiation of capecitabine, 18 patients (34.6%) had new onset cardiovascular symptoms, 6 (11.5%) had new onset physical signs and 17 (32.6%) had new onset ECG findings. New onset ECG findings included prolonged corrected QT interval (n = 10, 19.2%) and prolonged PR interval (n = 3, 5.8%). Severe adverse capecitabine-induced cardiac side effects were observed in 5.8% of the patients, but none of the patients had myocardial infarction or died. Conclusion: Cardiac events are not rare during capecitebine treatment and patients should be followed closely to avoid cardiac morbidity and mortality.

show abstract

Section: Discussionmentioning

confidence: 99%

Clinical and Electrocardiography Changes in Patients Treated with Capecitabine

Koca

Salman²,

Ünek³

et al. 2011

Chemotherapy

View full text Add to dashboard Cite

show abstract

“…Chx has been reported to cause cardiac toxicity, thrombus formation or even aortic dissection in an otherwise healthy aorta. 15–17 Scarce evidence suggests a correlation between malignancy, Chx and aneurysmal degeneration. 6,18 In these few case reports, 6,18 growth rate substantially exceeded the expected 0.11 cm expansion per year for aneurysms 3–3.9 cm 19 or 0.13 ± 0.15 cm per year for ectatic aortas between 2.5 and 2.9 cm.…”

Section: Discussionmentioning

confidence: 99%

The effect of recent chemotherapy in aorto-iliac aneurysm repair

et al. 2013

View full text Add to dashboard Cite

The aim of the study was to investigate the effect of recent chemotherapy (Chx) on outcome of aorto-iliac aneurysm (AAA) repair. The 2005-2010 American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP) database was queried to identify vascular patients undergoing AAA repair within 30 days after Chx. Seventy-one patients underwent AAA repair within 30 days of receiving Chx, group A (71 ± 8.4 years, 77.5% males) and 20,024 patients underwent AAA repair without prior Chx, group B (73 ± 9 years, 79.2% males). The two groups did not significantly differ with respect to open or endovascular repair (open repair A: 32%, B: 35%, P = 0.66). However, patients in group A presented more often as emergent cases (A: 27%, B: 12%, P = 0.001). Multivariable regression analysis for emergent cases after adjustment for relevant confounders also demonstrated that patients with recent Chx present more often as emergency (P = 0.001, odds ratio [OR]: 2.4). Thirty-day non-surgical complications were more common in group A (A: 25%, B: 16.5%, P = 0.046) while surgical complications were equivalent (A: 15.5%, B: 12.3%, P = 0.414). Risk of death was significantly higher in group A in univariate analysis (A: 13%, B: 5%, P = 0.005, OR: 2.6). Patients who receive Chx within 30 days prior to AAA repair present more frequently as emergencies leading to higher mortality. The reason for this cannot be sufficiently explained by the current database but patient selection for elective repair or the effect of Chx on the natural course of AAA may play a role.

show abstract

“…For example, treatment of breast cancer patients with capecitabine can cause cardiovascular toxicity [1], and treatment with platinum-based compounds can cause nephrotoxicity [for a review, see [2]].…”

Section: Introductionmentioning

confidence: 99%

Methyl Sulfone Manifests Anticancer Activity in a Metastatic Murine Breast Cancer Cell Line and in Human Breast Cancer Tissue - Part 2: Human Breast Cancer Tissue

et al. 2013

View full text Add to dashboard Cite

Background: Methyl sulfone is a small molecule that reverses cancerous phenotypes of a melanoma cell line. Here, we sought to determine whether methyl sulfone was effective against human breast cancer tissue. Methods: We studied normal and cancerous breast tissue obtained from 17 patients. Results: Methyl sulfone introduced structural order, with cancer tissue taking on the morphology of normal in vivo breast tissue; this structural order was sustainable over long-term culture. Methyl sulfone promoted proper wound healing, including migration of cells into wounded areas and establishment of stable contact inhibition once wounds were covered. Methyl sulfone decreased expression of two breast stem cell marker proteins, HCAM and OCT3/4, which are associated with aberrantly rapid migration of metastatic cells. Finally, normal and cancerous primary breast cells remained viable and healthy in methyl sulfone culture for at least 90 days. Conclusion: Methyl sulfone reintroduced a normal structural phenotype to human breast cancer tissues.

show abstract

Case Report of Acute Aortic Dissection during Treatment with Capecitabine for a Late Recurrence of Breast Cancer

Cited by 7 publications

References 15 publications

Clinical and Electrocardiography Changes in Patients Treated with Capecitabine

Clinical and Electrocardiography Changes in Patients Treated with Capecitabine

The effect of recent chemotherapy in aorto-iliac aneurysm repair

Methyl Sulfone Manifests Anticancer Activity in a Metastatic Murine Breast Cancer Cell Line and in Human Breast Cancer Tissue - Part 2: Human Breast Cancer Tissue

Contact Info

Product

Resources

About